Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NovalGen logo — Breakthrough bispecific antibody therapies harnessing the im...

NovalGen

Breakthrough bispecific antibody therapies harnessing the immune system to fight cancer

Founded 2019 United Kingdom United Kingdom 15 employees

General Information

Company Name NovalGen
Founded Year 2019
Location United Kingdom United Kingdom +1
Employees 15
Social

Get notified when NovalGen moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About NovalGen

NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond

No funding data available for NovalGen yet.

Get notified when NovalGen raises funding

NovalGen Alternatives & Competitors

NovalGen vs
Guangzhou LintonPharm Co.,Ltd.
Guangzhou LintonPharm Co.,Ltd. China

Science & Conscience for Life Affordable Biomedical Cure

5 employees
Biotechnology, Life Sciences
NovalGen vs
Probmet Therapeutics
Probmet Therapeutics Denmark

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastat...

Convertible Note
2 employees
Health Care, Health and Wellness
NovalGen vs
Adept Biopharma
Adept Biopharma

Creating groundbreaking immuno-therapeutics, leveraging world-class antibody discovery, and pioneeri...

Angel
Biotechnology, Health Care

FAQ About NovalGen

Breakthrough bispecific antibody therapies harnessing the immune system to fight cancer
NovalGen was founded in 2019.
NovalGen is headquartered in United Kingdom.
NovalGen has approximately 15 employees.
Top alternatives and competitors to NovalGen include Guangzhou LintonPharm Co.,Ltd., Probmet Therapeutics, Adept Biopharma, Akeso Biopharma, Elpiscience Biopharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NovalGen and Guangzhou LintonPharm Co.,Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors NovalGen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy